Semaglutide in Australia: Research Context
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist with a half-life of approximately 7 days, enabling once-weekly dosing. It shares 94% sequence homology with native human GLP-1, modified with a C18 fatty diacid acylation at lysine-26 that confers albumin binding and protects against DPP-4 degradation. This pharmacokinetic profile, near-continuous receptor engagement for 7 days, is the basis for its sustained appetite suppression and metabolic effects.
Semaglutide has the largest and most mature clinical evidence base of any compound in the GLP-1 class. The STEP programme established it as a reference standard in metabolic research; the SUSTAIN programme characterised its glycaemic effects in type 2 diabetes; and the SELECT trial (2023) demonstrated cardiovascular benefits in non-diabetic obesity. No other GLP-1 class compound has equivalent depth of completed outcomes data as of 2026.
Why semaglutide remains the research benchmark Deepest completed Phase 3 dataset in the GLP-1 class · SELECT trial: 20% MACE reduction in non-diabetic obesity, first such evidence for any GLP-1 agonist · STEP 1: 14.9% mean weight loss at 68 weeks · Active research in Alzheimer's, addiction, NASH/MASH, heart failure as of 2026
STEP Trial Programme: Key Efficacy Data
The STEP programme (Semaglutide Treatment Effect in People with Obesity) is the pivotal dataset for semaglutide in obesity research. Key trials:
| Trial | Population | Duration | Key outcome |
|---|---|---|---|
| STEP 1 | Obesity, no T2D | 68 weeks | 14.9% mean weight loss at 2.4mg |
| STEP 2 | Obesity + T2D | 68 weeks | 9.6% weight loss (T2D population) |
| STEP 3 | Obesity + intensive lifestyle | 68 weeks | Up to 16% with lifestyle co-intervention |
| STEP 4 | Maintenance post-loss | 68 weeks | 6.9% regain after stopping vs −2.4% continued |
| SELECT | Non-diabetic obesity + CVD | ~34 months | 20% MACE reduction vs placebo |
STEP 4's discontinuation data is mechanistically significant for researchers: participants who stopped semaglutide regained approximately two-thirds of lost weight within one year, supporting the hypothesis that chronic receptor engagement is required for sustained metabolic effects. This has implications for research protocol design, particularly for protocols investigating maintenance endpoints.
Reconstitution and Dosing Reference for Australian Researchers
RetaLABS Semaglutide is supplied lyophilised. Use bacteriostatic water for reconstitution. The STEP 1 maintenance dose was 2.4mg/week; the escalation schedule used in trial was gradual, starting at 0.25mg/week.
Common research concentrations:
| Vial size | BAC water added | Concentration | Volume per 0.5mg | Volume per 1mg | Volume per 2.4mg |
|---|---|---|---|---|---|
| 5mg | 2.5 mL | 2 mg/mL | 0.25 mL | 0.50 mL | 1.20 mL |
| 5mg | 5.0 mL | 1 mg/mL | 0.50 mL | 1.00 mL | 2.40 mL |
| 10mg | 5.0 mL | 2 mg/mL | 0.25 mL | 0.50 mL | 1.20 mL |
Store lyophilised vials at −20°C. Store reconstituted solution at 2–8°C; use within 4–6 weeks. Do not freeze reconstituted solution. Rotate injection sites weekly. Use the RetaLABS reconstitution calculator for custom volumes. For full storage protocols, see the Peptide Reconstitution & Storage Guide.
How Semaglutide Compares to Newer Compounds in Australia
Semaglutide occupies a distinct position in the Australian research peptide landscape: it has the most evidence, but is no longer the most efficacious compound in the class:
| Metric | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Best Phase trial weight loss | 14.9% (68 weeks) | 20.9% (72 weeks) | 24.2% (48 weeks) |
| Cardiovascular outcomes trial | Completed (SELECT) | Ongoing (MMO) | Ongoing (SYNERGY) |
| Phase 3 completion | Multiple completed | Multiple completed | Ongoing (TRIUMPH) |
| GI AE burden | Lower | Lower | Higher at max dose |
| Receptor targets | GLP-1R only | GLP-1R + GIPR | GLP-1R + GIPR + GcgR |
Semaglutide's research advantage is its evidence depth; it is the only GLP-1 compound with a completed cardiovascular outcomes trial in non-diabetic obesity (SELECT). For research specifically investigating cardiovascular endpoints or requiring the most established long-term safety profile, semaglutide remains the reference standard. For weight loss efficacy endpoints, newer compounds have surpassed it.
For detailed comparisons, see Retatrutide vs Semaglutide and the GLP-1 Peptides Comparison Guide.